Navigation Links
Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/12/2009

324,875 Convertible preferred stock: $0.001 par value; 7,593,091 shares authorized; 0 shares issued and outstanding at September 30, 2009; Series A - 60,212, Series B - 1,126,020, Series C - 2,838,091 and Series D - 3,325,647 shares issued and outstanding at December 31, 2008 - 71,036,951 Stockholders' equity (net capital deficiency): Common stock, $0.001 par value; 100,000,000 shares authorized; 13,336,431 and 454,676 shares issued and outstanding at September 30, 2009 and December 31, 2008, respectively 13,336 455 Additional paid-in capital 157,516,702 1,503,841 Accumulated deficit (84,567,159) (65,111,433) Accumulated other comprehensive income 64,758 25,825 ------ ------ Total stockholders' equity (net capital deficiency) 73,027,637 (63,581,312) ---------- ----------- Total liabilities, convertible preferred stock and stockholders' equity (net capital deficiency) $100,016,740 $13,780,514 ============ ===========
    Contact:

    Transcept Pharmaceuticals, Inc.
    Greg Mann
    Director, Corporate Communications
    (510) 215-3567
    gmann@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
2. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
3. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
4. Transcept Pharmaceuticals to Report First Quarter 2009 Results
5. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
6. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
7. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
8. Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
9. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
10. Endo Pharmaceuticals and LecTec Settle Patent Dispute
11. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... leading OTC brands from GSK in an all cash ... clear demonstration of Perrigo,s unique ability to maximize brand ... 36 countries.  Perrigo Chairman, President and ... excited to complete this transaction, which clearly demonstrates our ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been a licensed ... "I specialize in manual therapy, and my invention will provide headache sufferers a ... additional muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates ...
(Date:8/29/2015)... ... ... Next weekend is Labor Day weekend, the last bash of the season ... year). For IT security personnel, it should also mark the perfect time to make ... than a simple headache. , Joe Caruso, founder and CEO-CTO of Global Digital ...
(Date:8/29/2015)... TX (PRWEB) , ... August 29, 2015 , ... ... allows the company to freely market and sell Arterosil and Arterosil HP, and ... Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment ... position they are applying for, they are unable to pass the initial drug test ... drug testing policies in order to be able to hire long-term, skilled talent. (1) ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a non-invasive ... two years, the longest of any cellulite reduction system currently on the market. ... solution for their cellulite, according to Dr. Robert Weiss, director of the premier MD ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... said on Friday that more than 300 people reported ill ... Olive Garden restaurant at Indianapolis// last weekend, a day after ... restaurants. ,The restaurant is closed temporarily and health ... ,Leftover food and stool samples were collected ...
... prevalence of obesity could bankrupt the health system, warn doctors ... over half the population is overweight and more than one ... Obese people are at high risk of multiple health problems, ... is currently estimated at up to 9%, and the overall ...
... Supplement, a product containing the drug estazolam, which might make ... months. // ,Estazolam belongs to benzodiazepines class of ... as it may have a number of side effects like ... is not legal to sell it in Canada. ,Hence, ...
... pneumonia in the Downtown Eastside with more than 70 cases ... Downtown Eastside has clearly pushed the health supporting system to ... memo, David Butcher, vice-president of medicine for Northern Health, warned ... limiting the availability of ICU beds. ,"At the ...
... a weekend night over, ice has become an integral part of ... drugs used by people along with ice are marijuana, ketamine, heroin ... mask the effects of these drugs when they have report to ... pleasurable sensation in my head, after which they usually smoke ice ...
... Expression of two different proteins taken from primary tumor ... to nearby lymph nodes, according to researchers who// say ... stage those patients whose disease is likely to metastasize. ... Research, the researchers say over-expression of one unidentified protein ...
Cached Medicine News:Health News:Obesity Could Bankrupt the Health System, Warn Doctors 2Health News:Researchers Find Two Biomarkers With Potential to Predict Breast Cancer Spread 2Health News:Researchers Find Two Biomarkers With Potential to Predict Breast Cancer Spread 3Health News:Researchers Find Two Biomarkers With Potential to Predict Breast Cancer Spread 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: